The workgroup that generated the guideline included experts in primary care, gynecology, surgical oncology, medical oncology, radiation oncology, and nursing, along with a cancer survivor who provided a patient perspective.
Healthcare providers managing the needs of survivors of breast cancer may not always be aware of the nuances of clinical management that these patients need. With a 90% 5-year survival rate, breast cancer survivors make up nearly 40% of the overall women cancer survivors. To support primary care physicians as they guide patients through their wellness and quality of life (QoL) concerns, the American Cancer Society (ACS) and the American Society of Clinical Oncology (ASCO) released an updated ACS/ASCO Breast Cancer Survivorship Care Guideline, which, the committee writes in the Journal of Clinical Oncology (JCO), “will provide comprehensive, holistic recommendations specific to post-treatment breast cancer clinical care to help primary care clinicians better manage potential long-term and late effects and to provide timely and appropriate screening and surveillance to improve the overall health and QoL of breast cancer survivors.”
The workgroup included experts in primary care, gynecology, surgical oncology, medical oncology, radiation oncology, and nursing, along with a cancer survivor who provided a patient perspective. Of more than a 1000 articles that were reviewed, 237 met the inclusion criteria. The final recommendations were then a compendium of literature-based evidence and expert consensus opinion.
The guideline makes recommendations that address the following:
a. History and physical
b. Screening the breast for local recurrence or a new primary breast cancer
c. Laboratory testing and imaging
d. Signs of recurrence
e. Risk evaluation and genetic counseling
f. Endocrine treatment impacts, ymptom management
a. Cancer screenings in the average-risk patient
a. Body image concerns
b. Lymphedema
c. Cardiotoxicty
d. Cognitive impairment
e. Distress, depression, anxiety
f. Fatigue
g. Bone health
h. Musculoskeletal health
i. Pain and neuropathy
j. Infertility
k. Sexual health
l. Premature menopause/hot flashes
a. Information
b. Obesity
c. Physical activity
d. Nutrition
e. Smoking cessation
a. Survivorship care plan
b. Communication with oncology team
c. Inclusion of family
1. Surveillance for breast cancer recurrence2. Screening for second primary cancers3. Assessment and management of physical and psychosocial long-term and late effects of breast cancer and treatment4. Health promotion5. Care coordination/practice implicationsIn addition to being published in the JCO, the guideline has also been published in CA: A Cancer Journal for Clinicians. Both ACS and ASCO have of course posted these guidelines on the organizations’ respective websites, and the ASCO Practice Implementation Network is ensuring wide distribution of the guideline.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More